Definitive Contract 75N91018C00019
Award Date
9/17/18
Potential Completion Date
4/15/20
Potential Value
$289K
Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Wynantskill, NY, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services (DHHS), to Theranano LLC, a small disadvantaged, woman-owned business. The $300,000 fixed-price contract is for research on the sustained delivery of PARP inhibitors for cancer chemoprevention. This SBIR contract was issued under the DHHS/NIH/CDC SBIR Contract Solicitation PHS 2018-1, which sought proposals from small...
This is a $399,975.00 Phase I Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Chromologic LLC, a minority-owned small business. The contract is for the development of an "Organ-on-VascularNet Model for In Vitro Evaluation of Radiation and Drug Therapies." This research supports NCI's mission to address critical needs in cancer treatment and prevention. The contract has a firm...
This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Zymeron Corporation, a Minority Owned Small Business. The $349,790 Firm Fixed Price contract supports research and development of "Targeted and Sustained Release Microparticles for Colon Cancer Chemoprevention." This work is part of the NIH/CDC SBIR Program, which aims to stimulate technological...
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>
This is a $289,828.00 SBIR Phase I contract awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Nicolalde R&D LLC, a minority-owned, self-certified small disadvantaged business. The contract is a firm fixed-price definitive contract with a completion date of November 30, 2021. The SBIR (Small Business Innovation Research) Program Phase I award indicates this contract is for early-stage research and development activities. As a...
<p>This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian agency, to Sibtech, Inc., a for-profit manufacturer, in the amount of $2,256,052.35. The contract is for the development of systemic radionuclide therapy targeted to VEGF receptors in tumor vasculature. The contract has a firm fixed price pricing type and an ultimate completion date of October 31, 2021. This contract is a set-aside for small businesses.</p>
This is a $455,000 firm fixed price contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) at the Department of Health and Human Services (HHS). The contract was awarded to Mrimath LLC, a small disadvantaged, woman-owned limited liability company, for a Small Business Innovation Research (SBIR) Phase I project related to Artificial Intelligence-aided imaging for cancer prevention, diagnosis, and monitoring. The contract has a...
This is a Phase II Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. Department of Health and Human Services (HHS), to Nortis Inc., a for-profit manufacturer of biotechnology products and services. The contract, valued at $1,988,728.00, is for the development of a "vascularized tumor-microenvironment assay" to support the screening of anti-cancer drugs. This contract is designated as a Total Small Business...
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a for-profit subchapter S corporation. The $224,687.00 firm-fixed-price contract, awarded on September 19, 2016, is for the SBIR PHASE I TOPIC 352 CELL-BASED MODELS FOR PROSTATE CANCER HEALTH DISPARITY RESEARCH project, with a planned completion date of June 18, 2017. This contract was set aside for small businesses.</p>
This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute (NCI) to Inlighta Biosciences L.L.C., a woman-owned small business. The $298,230.00 firm fixed-price contract is for a Phase I Small Business Innovation Research (SBIR) project titled "Non-Invasive Subtyping of Aggressive Tumor and Its Environment" as part of the NCI Cancer Moonshot initiative. The original solicitation was issued under the NIH/CDC...